A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

Evaluation of Different Dose Escalation Regimens for NNC0662-0419 in Participants With Obesity

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07639021

Enrollment

230

Registered

2026-06-10

Start date

2026-06-09

Completion date

2027-07-12

Last updated

2026-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

Interventions

DRUGNNC0662-0419

NNC0662-0419 will be administered subcutaneously.

DRUGSemaglutide

Semaglutide will be administered subcutaneously.

DRUGNNC0662-0419 Placebo

Placebo matched to NNC0662-0419 will be administered subcutaneously.

DRUGSemaglutide placebo

Placebo matched to semaglutide will be administered subcutaneously.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening. * Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation.

Exclusion criteria

* Known or suspected hypersensitivity to study intervention(s) or related products. * Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening. * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus.

Design outcomes

Primary

Measure	Time frame	Description
Number of gastrointestinal adverse events	From week 0 to week 39	Measured as number of events.

Secondary

Measure	Time frame	Description
Relative change in body weight	From week 0 to week 32	Measured as percentage (%) change.
Change in body mass index (BMI)	From week 0 to week 32	Measured as kilogram per square meter (kg/m\^2).

Countries

Puerto Rico, United States

Contacts

CONTACTNovo Nordisk

clinicaltrials@novonordisk.com(+1) 866-867-7178

STUDY_DIRECTORClinical Transparency (dept. 2834)

Novo Nordisk A/S

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 11, 2026